Danaher Boosts 2026 EPS Guidance After Mixed Q1 Results
Event summary
- Danaher reported Q1 2026 revenue of $6.0B, up 3.5% YoY, with non-GAAP core revenue growing 0.5%.
- Adjusted EPS grew 9.5% to $2.06, prompting an upward revision of full-year guidance to $8.35-$8.55.
- Bioprocessing and Life Sciences segments showed strength, offsetting weaker Diagnostics performance.
- Company announced plans to acquire Masimo Corporation, a provider of patient monitoring solutions.
The big picture
Danaher's Q1 results reflect a mixed performance across segments, with Life Sciences and Bioprocessing offsetting weaker Diagnostics. The planned Masimo acquisition signals a strategic push into patient monitoring, aligning with broader industry trends toward integrated healthcare solutions. The company's strong cash flow position supports its expansion plans, but integration risks and regulatory approvals remain key variables.
What we're watching
- Integration Challenges
- How Danaher will integrate Masimo and realize expected synergies.
- Segment Performance
- Whether Life Sciences and Bioprocessing can sustain momentum amid Diagnostics weakness.
- Regulatory Hurdles
- The pace at which Masimo acquisition clears regulatory approvals.
Related topics